Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for technology industry professionals · Thursday, March 28, 2024 · 699,597,682 Articles · 3+ Million Readers

Voyager Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call

CAMBRIDGE, Mass., Feb. 18, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced plans to host its fourth quarter and full year 2018 financial results and corporate highlights conference call and live webcast on Tuesday, February 26, 2019 at 4:30 p.m. EST.

The live call may be accessed by dialing (877) 851-3834 for domestic callers, or +1 (631) 291-4595 for international callers, and referencing conference ID number 9672838. A live audio webcast of the conference call will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. Voyager’s pipeline focuses on severe neurological diseases in need of effective new therapies, including Parkinson’s disease, a monogenic form of ALS called SOD1, Huntington’s disease, Friedreich’s ataxia, neurodegenerative diseases related to defective or excess aggregation of tau protein in the brain including Alzheimer’s disease and severe, chronic pain. Voyager has strategic collaborations with Neurocrine Biosciences, AbbVie and Sanofi Genzyme. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information on Voyager Therapeutics, please visit the company’s website at www.voyagertherapeutics.com.

Investor Relations:
                    Matt Osborne
                    Vice President of Corporate Affairs, Communications and Investor Relations
                    857-259-5353
                    mosborne@vygr.com
                    
                    Media:
                    Sheryl Seapy
                    W2O Group
                    949-903-4750
                    sseapy@w2ogroup.com

Voyager Therapeutics Logo.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release